Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease

Journal of Neurochemistry

Volumn 85, Issue 3, 2003, Pages 645-650

  Fessel, Joshua P ^a   Hulette, Christine ^c   Powell, Suzanne ^d   Roberts II, L Jackson ^a,b   Zhang, Jing ^b,e  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Free radicals; Isofurans; Isoprostanes; Lipid peroxidation; Oxidative stress; Parkinson's disease

Indexed keywords

ISOPROSTANE; PROSTAGLANDIN F2; FURAN DERIVATIVE; ISOPROSTANE DERIVATIVE; PHOSPHOLIPID;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN MITOCHONDRION; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; ESTERIFICATION; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIPID PEROXIDATION; MALE; NEUROPATHOLOGY; OXIDATIVE STRESS; OXYGEN TENSION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SHY DRAGER SYNDROME; SUBSTANTIA NIGRA; CHEMISTRY; COMPARATIVE STUDY; ISOMERISM; METABOLISM; PATHOLOGY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; F2-ISOPROSTANES; FEMALE; FURANS; HUMANS; ISOMERISM; LEWY BODY DISEASE; MALE; MULTIPLE SYSTEM ATROPHY; OXIDATIVE STRESS; PARKINSON DISEASE; PHOSPHOLIPIDS; SUBSTANTIA NIGRA;

EID: 0037660183     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2003.01709.x     Document Type: Article

References (39)

1. Alam Z. I., Daniel S. E., Lees A. J., Marsden D. C., Jenner P. and Halliwell B. (1997) A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem. 69, 1326-1329.
2. Beal M. F. (1996) Mitochondria, free radicals, and neurodegeneration. Curr. Opin. Neurobiol. 6, 661-666.
3. Betarbet R., Sherer T. B., MacKenzie G., Garcia-Osuna M., Panov A. V. and Greenamyre J. T. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3, 1301-1306.
4. Cohen G. (1983) The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence. J. Neural Transmsuppl. 19, 89-103.
5. Di Monte D. A. (1991) Mitochondrial DNA and Parkinson's disease. Neurology 41, 38-42; discussion 42-33.
6. Fessel J. P., Porter N. A., Moore K. P., Sheller J. R., Roberts L. J., II (2002) Discovery of new products of lipid peroxidation formed in vivo with a substituted tetrahydrofuran ring (isofurans) that are favored by increased oxygen tension. Proc. Natl Acad. Sci. USA 99, 16713-16718.
7. Flanagan S. W., Anderson R. D., Ross M. A. and Oberley L. W. (2002) Overexpression of manganese superoxide dismutase attenuates neuronal death in human cells expressing mutant (G37R) Cu/Zn-superoxide dismutase. J. Neurochem. 81, 170-177.
8. Freeman B. A. and Crapo J. D. (1982) Biology of disease. Free radicals and tissue injury. Lab. Invest. 47, 412-426.
9. Graham D. G. (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14, 633-643.
10. Graham D. G., Tiffany S. M., Bell W. R. Jr and Gutknecht W. F. (1978) Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 14, 644-653.
11. 2 in cells? Adv. Exp. Med. Biol. 454, 415-423.
12. Gu M., Gash M. T., Cooper J. M., Wenning G. K., Daniel S. E., Quinn N. P., Marsden C. D. and Schapira A. H. (1997) Mitochondrial respiratory chain function in multiple system atrophy. Mov. Disord. 12, 418-422.
13. Halliwell B. and Gutteridge J. M. C. (1999) Free Radicals in Biology and Medicine, 3nd edn. Oxford University Press, Oxford, UK.
14. Hastings T. G., Lewis D. A. and Zigmond M. J. (1996) Reactive dopamine metabolites and neurotoxicity: implications for Parkinson's disease. Adv. Exp. Med. Biol. 387, 97-106.
15. Ide T., Tsutsui H., Kinugawa S., Utsumi H., Kang D., Hattori N., Uchida K., Arimura K., Egashira K. and Takeshita A. (1999) Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ. Res. 85, 357-363.
16. Ito K., Nioka S. and Chance B. (1990) Oxygen dependence of energy state and cardiac work in the perfused rat heart. Adv. Ex.p Med. Biol. 277, 449-457.
17. Langston J. W., Ballard P., Tetrud J. W. and Irwin I. (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979-980.
18. Li H. and Dryhurst G. (1997) Irreversible inhibition of mitochondrial complex I by 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1): a putative nigral endotoxin of relevance to Parkinson's disease. J. Neurochem. 69, 1530-1541.
19. Liu R., Li B., Flanagan S. W., Oberley L. W., Gozal D. and Qiu M. (2002) Increased mitochondrial antioxidative activity or decreased oxygen free radical propagation prevent mutant SOD1-mediated motor neuron cell death and increase amyotrophic lateral sclerosis-like transgenic mouse survival. J. Neurochem. 80, 488-500.
20. Lowe J., Graham L. and Leigh P. N. (1997) Disorders of movement and system degeneration,. In: Greenfield's Neuropathology, 6th Edn, Vol. II (Graham D. I. and Lantos P. L., eds), pp. 281-366. Arnold, London.
21. McKeith I. G., Galasko D., Kosaka K., Perry E. K., Dickson D. W., Hansen L. A., Salmon D. P., Lowe J., Mirra S. S., Byrne E. J., Lennox G., Quinn N. P., Edwardson J. A., Ince P. G., Bergeron C., Burns A., Miller B. L., Lovestone S., Collerton D., Jansen E. N., Ballard C., de Vos R. A., Wilcock G. K., Jellinger K. A. and Perry R. H. (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47, 1113-1124.
22. Mirra S. S. (1997) The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer's disease: a commentary. Neurobiol. Aging 18, S91-S94.
23. Montine T. J., Underhill T. M., Linney E. and Graham D. G. (1994) Fibroblasts that express aromatic amino acid decarboxylase have increased sensitivity to the synergistic cytotoxicity of 1-dopa and manganese. Toxicol. Appl. Pharmacol. 128, 116-122.
24. Montine T. J., Picklo M. J., Amarnath V., Whetsell W. O. Jr and Graham D. G. (1997) Neurotoxicity of endogenous cysteinylcatechols. Exp. Neurol. 148, 26-33.
25. Montine T. J., Sidell K. R., Crews B. C., Markesbery W. R., Marnett L. J., Roberts II L. J. and Morrow J. D. (1999a) Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology 53, 1495-1498.
26. 2-isoprostanes are elevated in Huntington's disease. Neurology 52, 1104-1105.
27. Morrow J. D., Chen Y., Brame C. J., Yang J., Sanchez S. C., Xu J., Zackert W. E., Awad J. A. and Roberts L. J. (1999) The isoprostanes: unique prostaglandin-like products of free-radical-initiated lipid peroxidation. Drug Metab. Rev. 31, 117-139.
28. Newell K. L., Hyman B. T., Growdon J. H. and Hedley-Whyte E. T. (1999) Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer's disease. J. Neuropathol. Exp. Neurol. 58, 1147-1155.
29. Perry T. L., Godin D. V. and Hansen S. (1982) Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci. Lett. 33, 305-310.
30. 2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J. 12, 1777-1783.
31. Przedborski S. and Jackson-Lewis V. (1998) Mechanisms of MPTP toxicity. Mov. Disord 13, 35-38.
32. Reich E. E., Markesbery W. R., Roberts L. J., 2nd Swift L. L., Morrow J. D. and Montine T. J. (2001) Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. Am. J. Pathol 158, 293-297.
33. 2)-isoprostanes as an index of oxidative stress in vivo. Free Radic. Biol. Med. 28, 505-513.
34. Schapira A. H. (1998) Mitochondrial dysfunction in neurodegenerative disorders. Biochim. Biophys. Acta 1366, 225-233.
35. Schapira A. H., Hartley A., Cleeter M. W. and Cooper J. M. (1993) Free radicals and mitochondrial dysfunction in Parkinson's disease. Biochem. Soc. Trans. 21, 367-370.
36. Siciliano G., D'Avino C., Del Corona A., Barsacchi R., Kusmic C., Rocchi A., Pastorini E. and Murri L. (2002) Impaired oxidative metabolism and lipid peroxidation in exercising muscle from ALS patients. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 3, 57-62.
37. Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E. R. and Mizuno Y. (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl Acad. Sci. USA 93, 2696-2701.
38. Zhang J., Price J. O., Graham D. G. and Montine T. J. (1998) Secondary excitotoxicity contributes to dopamine-induced apoptosis of dopaminergic neuronal cultures. Biochem. Biophys. Res. Commun. 248, 812-816.
39. Zhang J., Perry G., Smith M. A., Robertson D., Olson S. J., Graham D. G. and Montine T. J. (1999) Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am. J. Pathol. 154, 1423-1429.